Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May;13(5):762-764.
doi: 10.1111/jdi.13765. Epub 2022 Feb 16.

Assessing liver fibrosis in all patients with type 2 diabetes and fatty liver disease: It's time to act now

Chi Ho Lee  1   2 , David T W Lui  1 , Karen S L Lam  1   2
Affiliations
Comment

Assessing liver fibrosis in all patients with type 2 diabetes and fatty liver disease: It's time to act now

Chi Ho Lee et al. J Diabetes Investig. 2022 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Systematic evaluation for diabetes complications including non‐alcoholic fatty liver disease (NAFLD). In patients with type 2 diabetes, NAFLD, especially in the presence of clinically significant fibrosis, should be viewed as an important diabetes complication, and be systematically evaluated as for the other classic diabetes complications, such as atherosclerotic cardiovascular diseases, diabetic kidney disease, retinopathy and neuropathy. ALT, alanine aminotransferase; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; DKD, diabetic kidney disease; DR, diabetic retinopathy; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; UACR, urine albumin : creatinine ratio.
See this image and copyright information in PMC

Comment on

  • Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
    Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, Loomba R, Chalasani N, Kowdley K, Hameed B, Wilson LA, Yates KP, Belt P, Lazo M, Kleiner DE, Behling C, Tonascia J; NASH Clinical Research Network (CRN). Sanyal AJ, et al. N Engl J Med. 2021 Oct 21;385(17):1559-1569. doi: 10.1056/NEJMoa2029349. N Engl J Med. 2021. PMID: 34670043 Free PMC article.

References

    1. Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta‐analysis. Gastroenterology 2020; 158: 1611–1625e1612. - PubMed
    1. Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 2021; 385: 1559–1569. - PMC - PubMed
    1. Kim D, Konyn P, Sandhu KK, et al. Metabolic dysfunction‐associated fatty liver disease is associated with increased all‐cause mortality in the United States. J Hepatol 2021; 75: 1284–1291. - PubMed
    1. Jarvis H, Craig D, Barker R, et al. Metabolic risk factors and incident advanced liver disease in non‐alcoholic fatty liver disease (NAFLD): a systematic review and meta‐analysis of population‐based observational studies. PLoS Med 2020; 17: e1003100. - PMC - PubMed
    1. Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 2021; 161: 1657–1669. - PMC - PubMed

MeSH terms